With over 287,000 reported adverse events, rising poison control cases, and growing legal action across the U.S., doctors, regulators, and attorneys are paying close attention
Semaglutide offers patients an effective, medically supervised path to sustainable weight loss
Tirzepatides long-term data is still accumulating but the profile looks favorable
Why they matter: Cardiovascular outcome trials (LEADER, SUSTAIN-6, REWIND, SELECT) have shown reductions in major adverse cardiovascular events
These options are chosen after reviewing body mass index, waist circumference, blood sugar, blood pressure, liver health, medication history, and other factors
Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study